Wednesday, July 8, 2026

pharma · Melanoma · Multiple Myeloma · RNA

Atrium Therapeutics

Atrium Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker RNA. Primary therapeutic focus areas include Melanoma, Multiple Myeloma, Germ Cell Tumor, Renal Carcinoma, Acut

10578 Science Center Dr, Suite 125, San Diego, California 92121, US HQ
2026 Founded
46 Employees
Public company Type
RNA · NYSE Ticker
Company details
Status
Public
HQ
10578 Science Center Dr, Suite 125, San Diego, California 92121, US
Founded
2026
Employees
46
Programs
31
Drugs
33
Patents
37
Clinical program

Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"

Unknown · gene therapy · Cancer

Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx" for Cancer is a Unknown program (gene_therapy) at Atrium Therapeutics with 1 ClinicalTrials.gov record(s).

← All Atrium Therapeutics projects Unknown gene therapy active

Internal code IRB00114240

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Atrium Therapeutics
Phase
Unknown
Modality
gene_therapy
Indication
Cancer
Status
active
Trials
1